Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities

Journal of Clinical Investigation

Volumn 113, Issue 12, 2004, Pages 1664-1675

  Nickoloff, Brian J ^a   Nestle, Frank O ^b  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ARSENIC; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD2 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EFALIZUMAB; ETANERCEPT; GROWTH FACTOR; HLA ANTIGEN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; LITHIUM; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MERCURY; METHOTREXATE; NEUROPEPTIDE; PIMECROLIMUS; PSORALEN; RAPAMYCIN; RHEUMATOID FACTOR; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; DERMATOLOGICAL AGENT;

ALLELE; CLINICAL TRIAL; CYTOKINE RELEASE; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; IMMUNOPATHOGENESIS; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; T LYMPHOCYTE; ULTRAVIOLET A RADIATION; ANIMAL; DISEASE MODEL; DISEASE PREDISPOSITION; IMMUNE SYSTEM; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNE SYSTEM; PSORIASIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 3042845754     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200422147     Document Type: Review

References (108)

1. Krueger, G., et al. 2001. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 137:280-284.
2. Bhalerao, J., and Bowcock, A.M. 1998. The genetics of psoriasis: a complex disorder of the skin and immune system. Hum. Mol. Genet. 7:1537-1545.
3. Henseler, T., and Christophers, E. 1985. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J. Am. Acad. Dermatol. 13:450-456.
4. Krueger, J.G. 2002. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46:1-23; quiz 23-26.
5. Nickoloff, B.J. 2001. Creation of psoriatic plaques: the ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint. J. Cutan. Pathol. 28:57-64.
6. Henseler, T., and Christophers, E. 1995. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 32:982-986.
7. Barker, J.N. 1991. The pathophysiology of psoriasis. Lancet. 338:227-230.
8. Saiag, P., Coulomb, B., Lebreton, C., Bell, E., and Dubertret, L. 1985. Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science. 230:669-672.
9. Ackermann, L., et al. 1999. Mast cells in psoriatic skin are strongly positive for interferon-gamma. Br. J. Dermatol. 140:624-633.
10. Raychaudhuri, S.P., Rein, G., and Farber, E.M. 1995. Neuropathogenesis and neuropharmacology of psoriasis. Int. J. Dermatol. 34:685-693.
11. Lowe, P.M., et al. 1995. The endothelium in psoriasis. Br. J. Dermatol. 132:497-505.
12. Gottlieb, A.B. 1988. Immunologic mechanisms in psoriasis. J. Am. Acad. Dermatol. 18:1376-1380.
13. Nickoloff, B.J. 1999. The immunologic and genetic basis of psoriasis. Arch. Dermatol. 135:1104-1110.
14. Valdimarsson, H., Baker, B.S., Jonsdottir, I., Powles, A., and Fry, L. 1995. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol. Today. 16:145-149.
15. Chang, J.C., et al. 1997. Persistence of T-cell clones in psoriatic lesions. Arch. Dermatol. 133:703-708.
16. Vollmer, S., Menssen, A., and Prinz, J.C. 2001. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from non-lesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J. Invest. Dermatol. 117:1296-1301.
17. Nickoloff, B.J. 1991. The cytokine network in psoriasis. Arch. Dermatol. 127:871-884.
18. Zhou, X., et al. 2003. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol. Genomics. 13:69-78.
19. Lomholt, G. 1963. Psoriasis: prevalence, spontaneous course, and genetics; a census study on the prevalence of skin diseases on the Faroe Islands. Copenhagen, Denmark. G.E.C.-Gad. 295 pp.
20. Farber, E.M., and Nall, M.L. 1974. The natural history of psoriasis in 5,600 patients. Dermatologica. 148:1-18.
21. Tiilikainen, A., Lassus, A., Karvonen, J., Vartiainen, P., and Julin, M. 1980. Psoriasis and HLA-Cw6. Br. J. Dermatol. 102:179-184.
22. Gudjonsson, J.E., et al. 2003. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br. J. Dermatol. 148:233-235.
23. Capon, F., Munro, M., Barker, J., and Trembath, R. 2002. Searching for the major histocompatibility complex psoriasis susceptibility gene. J. Invest. Dermatol. 118:745-751.
24. Nair, R.P., et al. 1997. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum. Mol. Genet. 6:1349-1356.
25. Trembath, R.C., et al. 1997. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum. Mol. Genet. 6:813-820.
26. International Psoriasis Genetics Consortium. 2003. The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am. J. Hum. Genet. 73:430-437.
27. Ishihara, M., et al. 1996. Genetic polymorphisms in the keratin-like S gene within the human major histocompatibility complex and association analysis on the susceptibility to psoriasis vulgaris. Tissue Antigens. 48:182-186.
28. Martin, M.P., et al. 2002. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J. Immunol. 169:2818-2822.
29. Nickoloff, B.J. 1999. Skin innate immune system in psoriasis: friend or foe? J. Clin. Invest. 104:1161-1164.
30. Tomfohrde, J., et al. 1994. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 264:1141-1145.
31. Speckman, R.A., et al. 2003. Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum. Genet. 112:34-41.
32. Helms, C., et al. 2003. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat. Genet. 35:349-356.
33. Bromley, S.K., et al. 2001. The immunological synapse. Annu. Rev. Immunol. 19:375-396.
34. Lebwohl, M., et al. 2003. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349:2004-2013.
35. Nickoloff, B.J., et al. 1993. Activated keratinocytes present bacterial-derived superantigens to T lymphocytes: relevance to psoriasis. J. Dermatol. Sci. 6:127-133.
36. Ellis, C.N., and Krueger, G.G. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345:248-255.
37. Abrams, J.R., et al. 2000. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192:681-694.
38. Weinshenker, B.G., Bass, B.H., Ebers, G.C., and Rice, G.P. 1989. Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J. Am. Acad. Dermatol. 20:1132-1133.
39. Gottlieb, A.B., et al. 2000. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J. Am. Acad. Dermatol. 43:595-604.
40. Gottlieb, S.L., et al. 1995. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1:442-447.
41. Werlen, G., Hausmann, B., Naeher, D., and Palmer, E. 2003. Signaling life and death in the thymus: timing is everything. Science. 299:1859-1863.
42. Sakaguchi, N., et al. 2003. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 426:454-460.
43. Alarcon-Riquelme, M.E. 2003. A RUNX trio with a taste for autoimmunity. Nat. Genet. 35:299-300.
44. Prokunina, L., et al. 2002. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32:666-669.
45. Tokuhiro, S., et al. 2003. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat. Genet. 35:341-348.
46. Itoh, K., et al. 2002. Cutting edge: negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton through Cbp-EBP50-ERM assembly. J. Immunol. 168:541-544.
47. Rioux, J.D., et al. 2001. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet. 29:223-228.
48. Yabuuchi, H., et al. 1999. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther. 289:768-773.
49. Rodriguez, P.C., et al. 2003. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 171:1232-1239.
50. Hewett, D., et al. 2002. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics. 79:305-314.
51. Matzinger, P. 2002. The danger model: a renewed sense of self. Science. 296:301-305.
52. Soumelis, V., et al. 2002. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3:673-680.
53. Nickoloff, B.J., and Naidu, Y. 1994. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad. Dermatol. 30:535-546.
54. Baker, B.S., et al. 2001. Skin T cell proliferative response to M protein and other cell wall and membrane proteins of group A streptococci in chronic plaque psoriasis. Clin. Exp. Immunol. 124:516-521.
55. Travers, J.B., et al. 1999. Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J. Clin. Invest. 104:1181-1189.
56. Curry, J.L., Qin, J.Z., Robinson, J., and Nickoloff, B.J. 2003. Reactivity of resident immunocytes in normal and prepsoriatic skin using an ex vivo skin-explant model system. Arch. Pathol. Lab. Med. 127:289-296.
57. Bonish, B., et al. 2000. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J. Immunol. 165:4076-4085.
58. Gerlini, G., et al. 2001. CD1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells. J. Invest. Dermatol. 117:576-582.
59. Curry, J.L., et al. 2003. Innate immune-related receptors in normal and psoriatic skin. Arch. Pathol. Lab. Med. 127:178-186.
60. Nestle, F.O., Turka, L.A., and Nickoloff, B.J. 1994. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest. 94:202-209.
61. Uyemura, K., Yamamura, M., Fivenson, D.F., Modlin, R.L., and Nickoloff, B.J. 1993. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J. Invest. Dermatol. 101:701-705.
62. Schlaak, J.F., et al. 1994. T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102:145-149.
63. Reich, K., et al. 2002. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J. Invest. Dermatol. 118:155-163.
64. Asadullah, K., et al. 2001. Interleukin-10 promoter polymorphism in psoriasis. J. Invest. Dermatol. 116:975-978.
65. Oestreicher, J.L., et al. 2001. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J. 1:272-287.
66. Bowcock, A.M., et al. 2001. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum. Mol. Genet. 10:1793-1805.
67. Nathan, C. 2002. Points of control in inflammation. Nature. 420:846-852.
68. Nickoloff, B.J., et al. 1991. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am. J. Pathol. 138:129-140.
69. Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., and Gurney, A.L. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910-1914.
70. Lee, E., et al. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199:125-130.
71. Ruckert, R., et al. 2000. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J. Immunol. 165:2240-2250.
72. Villadsen, L.S., et al. 2003. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J. Clin. Invest. 112:1571-1580. doi:10.1172/JCI200318986.
73. Albanesi, C., et al. 2000. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J. Invest. Dermatol. 115:81-87.
74. Ohta, Y., Hamada, Y., and Katsuoka, K. 2001. Expression of IL-18 in psoriasis. Arch. Dermatol. Res. 293:334-342.
75. Blumberg, H., et al. 2001. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 104:9-19.
76. Quinones, M.P., et al. 2004. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J. Clin. Invest. 113:856-866. doi:10.1172/JCI200420126.
77. Krueger, G.G., Bergstresser, P.R., Lowe, N.J., Voorhees, J.J., and Weinstein, G.D. 1984. Psoriasis. J. Am. Acad. Dermatol. 11:937-947.
78. Wrone-Smith, T., and Nickoloff, B.J. 1996. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98:1878-1887.
79. Boehncke, W.H., Dressel, D., Zollner, T.M., and Kaufmann, R. 1996. Pulling the trigger on psoriasis. Nature. 379:777.
80. Nickoloff, B.J., and Wrone-Smith, T. 1999. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am. J. Pathol. 155:145-158.
81. Kess, D., et al. 2003. CD4(+) T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J. Immunol. 171:5697-5706.
82. Nickoloff, B.J., Bonish, B., Huang, B.B., and Porcelli, S.A. 2000. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J. Dermatol. Sci. 24:212-225.
83. Gilhar, A., et al. 2002. Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J. Invest. Dermatol. 119:384-391.
84. Zeigler, M., et al. 2001. Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with Cyclosporin A and clobetasol propionate. Lab. Invest. 81:1253-1261.
85. Schon, M.P., et al. 2002. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat. Med. 8:366-372.
86. Zollner, T.M., et al. 2002. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J. Clin. Invest. 109:671-679. doi:10.1172/JCI200212736.
87. Boyman, O., et al. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-{alpha}. J. Exp. Med. 199:731-736.
88. Reynolds, N.J., and Al-Daraji, W.I. 2002. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin. Exp. Dermatol. 27:555-561.
89. Reitamo, S., et al. 2001. Efficacy of sirolimus (rapamycin) administered concomitantly with a subcherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br. J. Dermatol. 145:438-445.
90. Rappersberger, K., et al. 2002. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J. Invest. Dermatol. 119:876-887.
91. Antoni, C., and Manger, B. 2002. Infliximab for psoriasis and psoriatic arthritis. Clin. Exp. Rheumatol. 20(Suppl. 28):S122-S125.
92. Scheinfeld, N. 2003. Adalimumab (HUMIRA): a review. J. Drugs Dermatol. 2:375-377.
93. Mease, P.J., et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 356:385-390.
94. Leonardi, C.L., et al. 2003. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349:2014-2022.
95. Rutgeerts, P., et al. 2003. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment. Pharmacol. Ther. 17:185-192.
96. Asadullah, K., et al. 1998. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest. 101:783-794.
97. Trepicchio, W.L., et al. 1999. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. 104:1527-1537.
98. Ghoreschi, K., et al. 2003. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9:40-46.
99. de Fougerolles, A.R., et al. 2000. Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J. Clin. Invest. 105:721-729.
100. von Andrian, U.H., and Engelhardt, B. 2003. Alpha4 integrins as therapeutic targets in autoimmune disease. N. Engl. J. Med. 348:68-72.
101. Hugor, J.P., et al. 2001 Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 411:599-603.
102. Ogura, Y., et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 411:603-606.
103. Rahman, P., et al. 2003. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am. J. Hum. Genet. 73:677-681.
104. Lala, S., et al. 2003. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology. 125:47-57.
105. Weitz-Schmidt, G., et al. 2001. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:687-692.
106. Kumar, S., Boehm, J., and Lee, J.C. 2003. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2:717-726.
107. Changelian, P.S., et al. 2003. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 302:875-878.
108. Steed, P.M., et al. 2003. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science. 301:1895-1898.